- Nontuberculous mycobacteria
Clinical efficacy and safety of fluoroquinolone containing regimens in patients with Mycobacterium avium complex (MAC) pulmonary disease.
Eur Respir J. 2020 Jan 24;:
Incidence and Prevalence of Nontuberculous Mycobacterial Lung Disease in a Large U.S. Managed Care Health Plan, 2008-2015.
Ann Am Thorac Soc. 2020 Feb;17(2):178-185
Prescribing Patterns for Treatment of Mycobacterium avium Complex and M. xenopi Pulmonary Disease in Ontario, Canada, 2001-2013.
Emerg Infect Dis. 2019 07;25(7):
Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada.
BMC Pharmacol Toxicol. 2019 06 03;20(1):37
Guidelines-based treatment associated with improved economic outcomes in nontuberculous mycobacterial lung disease.
J Med Econ. 2019 May 16;:1
Radiologic types of Mycobacterium xenopi pulmonary disease: different patients with similar short-term outcomes.
Eur J Clin Microbiol Infect Dis. 2018 Dec 14;:
Relative risk of all-cause mortality in patients with nontuberculous mycobacterial lung disease in a US managed care population.
Respir Med. 2018 Dec;145:80-88
Eur Respir J. 2018 Nov 28;:
Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT): A Prospective, Open-Label, Randomized Study.
Am J Respir Crit Care Med. 2018 Sep 14;:
Clinician Investigator, Krembil Research Institute (Krembil)
Director Toronto Western Hospital Nontuberculous Mycobacterial Clinical and Research Program